Page last updated: 2024-09-04

conivaptan and thalidomide

conivaptan has been researched along with thalidomide in 3 studies

Compound Research Comparison

Studies
(conivaptan)
Trials
(conivaptan)
Recent Studies (post-2010)
(conivaptan)
Studies
(thalidomide)
Trials
(thalidomide)
Recent Studies (post-2010) (thalidomide)
18817649,7891,3854,342

Protein Interaction Comparison

ProteinTaxonomyconivaptan (IC50)thalidomide (IC50)
Cereblon isoform 4Magnetospirillum gryphiswaldense7.8
Prostaglandin G/H synthase 1Ovis aries (sheep)0.37
Prostaglandin G/H synthase 2Ovis aries (sheep)0.5
DNA damage-binding protein 1Homo sapiens (human)1.38
Protein cereblonHomo sapiens (human)1.38

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Hussar, DA1

Reviews

1 review(s) available for conivaptan and thalidomide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

2 other study(ies) available for conivaptan and thalidomide

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
New drugs 07, part I.
    Nursing, 2007, Volume: 37, Issue:2

    Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States

2007